Nancy U. Lin, MD of Dana-Farber Cancer Institute @DanaFarber discusses tucatinib vs. placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases
Read here: https://meetinglibrary.asco.org/record/185141/abstract
Advertisement